RESEARCH NOTE

Targeted sequencing of selected functional genes in patients with wild-type transthyretin amyloidosis

Inmaculada Moreno-Gázquez[1,7]* , Raquel Pérez-Palacios[2,7], Lucia Abengochea-Quílez[3,6,7], Carmen Lahuerta Pueyo[1,7], Ana Roteta Unceta Barrenechea[4,7], Alejandro Andrés Gracia[4,7], Miguel Angel Aibar Arregui[5,7] and Sebastián Menao Guillén[1,7]

Abstract

Objective Wild-type transthyretin (ATTRwt) amyloidosis is caused by the misfolding and deposition of the transthyretin protein (TTR) in the absence of mutations in the *TTR* gene. Studies regarding the variant form of ATTR amyloidosis (ATTRv) suggest that the presence of single-nucleotide polymorphisms (SNP) in genes other than the *TTR*, may influence the development of the disease. However, other genetic factors involved in the aetiopathogenesis of ATTRwt are currently unknown. This work investigates the presence of sequence variants in genes selected for their possible impact on ATTRwt amyloidosis. To do so, targeted sequencing of 84 protein-coding genes was performed in a cohort of 27 patients diagnosed with ATTRwt.

Results After applying quality and frequency filtering criteria, 72 rare or novel genetic variants were found. Subsequent classification according to the ACMG-AMP criteria resulted in 17 variants classified as of uncertain significance in 14 different genes. To our knowledge, this is the first report associating novel gene variants with ATTRwt amyloidosis. In conclusion, this study provides potential insights into the aetiopathogenesis of ATTRwt amyloidosis by linking novel coding-gene variants with the occurrence of the disease.

Keywords ATTRwt amyloidosis, Gene variants, Targeted sequencing, Transthyretin amyloidosis

*Correspondence:
Inmaculada Moreno-Gázquez
783161@unizar.es
[1] Department of Clinical Biochemistry, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
[2] Department of Anatomy, Embryology and Genetics, Veterinary Faculty, University of Zaragoza, Zaragoza, Spain
[3] Health Research Institute in Aragón, Zaragoza, Spain
[4] Department of Nuclear Medicine, Multihospital Nuclear Medicine Clinical Unit of Aragón, Zaragoza, Spain
[5] Department of Internal Medicine, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
[6] Department of Chemical and Environmental Engineering, Campus Río Ebro- Edificio I+D, University of Zaragoza, Zaragoza, Spain
[7] Basic Research in Internal Medicine Group, GIIS-084 (IIS Aragón), Zaragoza, Spain

Introduction

The misfolding of the transthyretin protein (TTR) leads to its aggregation and systemic extracellular deposition in the form of amyloid fibrils, causing ATTR amyloidosis. TTR misfolding can originate either from inherited mutations in the *TTR* gene, which results in the variant form of the disease (ATTRv), or it can develop spontaneously due to the incorrect folding of the non-mutated TTR, leading to the so-called wild-type ATTR (ATTRwt) amyloidosis. The latter usually affects elderly men and is accompanied by cardiac involvement [1, 2]. Several studies in patients with ATTRv amyloidosis suggest that the presence of single nucleotide polymorphisms (SNPs) in genes other than the *TTR* may influence the development of the disease, affecting its age of

Moreno-Gázquez *et al. BMC Research Notes*   (2023) 16:249

Page 2 of 8

onset [3–6]. However, it is currently unknown whether any genetic factors could be involved either in the onset or the development of ATTRwt amyloidosis.

In this work, we study the presence of variants in genes selected for their potential involvement in ATTRwt amyloidosis according to their function. We particularly focused on genes encoding proteases potentially involved in TTR cleavage and their inhibitors, genes encoding TTR-interacting proteins, extracellular chaperones, extracellular matrix (ECM) related proteins, and genes described in the literature to be altered in different types of amyloidosis. Specifically, we designed and performed targeted sequencing of a panel of 84 protein-coding genes in a cohort of patients diagnosed with ATTRwt amyloidosis.

Main text
Materials and methods
Participants
A total of 27 non-related patients diagnosed with ATTRwt amyloidosis were enrolled in the study. The age of the patients ranged between 68 and 92 years (average age 81 years, 77.8% male). Diagnosis was made following the criteria of Gillmore et al. for cardiac amyloidosis [7] and Sanger sequencing of the *TTR* gene to confirm ATTRwt, at the Hospital Clínico Universitario Lozano Blesa, in Zaragoza, Spain. Clinical features of all patients are summarized in Additional file 1: Table S1.

Gene selection and panel design
An Ion AmpliSeq On-Demand panel (Thermo Fisher Scientific) expanded with a spike-in panel was designed with 2 primer pools to sequence 84 genes. Information about the sequencing data produced in this study is available in Additional file 1: Tables S2, S3.

Genes were eligible for inclusion when meeting any of the following criteria:

(i) Being involved in any of the molecular pathways that could play a role in amyloid formation, such as proteolysis, protein folding and ECM maintenance.
(ii) Having SNPs associated in the literature with the age of onset of ATTRv amyloidosis.
(iii) Showing altered expression or methylation patterns in patients with ATTRv amyloidosis.
(iv) Reported as altered in other amyloidotic processes, e.g. Alzheimer's disease.
(v) Genes coding for proteins that interact with the TTR protein.

Genetic analysis
Genomic DNA was isolated from EDTA blood samples using the MagDEA DxSV kit (Precision System Science Co.). DNA libraries were constructed using the Ion AmpliSeq™ Kit, and sequenced on the Ion Chef™ Instrument according to the manufacturer's instructions.

Analysis of DNA sequencing data
Reads were aligned to the hg19 human reference genome using the Torrent Suite and IonReporter 5.10.5.0 software.

Filtering criteria for gene variants based on:

(1) Reads depth higher than 30.
(2) Exonic variants, and intronic variants located up to ± 7bp to the intron–exon boundary.
(3) Selection of rare or novel gene variants. Specifically, variants with a minor allele frequency (MAF) ≤ 1% in the Genome Aggregation Database (GnomAD), hence excluding frequent variants in general population with likely no clinical significance.

Variant prioritization and classification
Variants were classified and prioritized according to the criteria of the American College of Medical Genetics (ACMG) [8], based on: (i) their location in the DNA sequence; (ii) the variant predicted effect on the protein using variant pathogenicity prediction programs such as SIFT, PolyPhen-2 and MutationTaster; (iii) the predicted effect of the variant on the splicing site, using the splice prediction program Splice AI, (iv) their MAF in GnomAD database; and (v) their presence in the dbSNP polymorphism database and the ClinVar disease database. Variants were also analysed with the Varsome (https://varsome.com/) and Intervar (https://wintervar.wglab.org/) clinical interpretation online software packages.

Results
After applying the filtering criteria, 72 genetic variants were detected (Additional file 1: Table S4). According to the criteria established by the ACMG [8], 55 of the filtered variants were classified as benign or likely benign. The remaining 17 gene variants, from a total of 14 different genes, were classified as of uncertain significance (VUS). All variants were found in heterozygosis. Detailed information of the identified variants is shown in Table 1.

The identified VUS were distributed among 9 of the subjects under study (Fig. 1) and corresponded to the

Moreno-Gázquez *et al. BMC Research Notes*   (2023) 16:249

Page 3 of 8

Table 1 Characteristics of variants of uncertain significance found in the study

Functional category	Gene	Sample	dbSNP ID	Transcript	Nucleotide change	Protein change	Allele Frequency in our study	MAFa in GnomAD v2.1.1	ClinVar Classification	SIFT[b]	PolyPhen-2[c]	Mutation Taster[d]	SpliceAI[e]
Altered expression patterns in ATTR amyloidosis	TF:	M14	rs121918677	ENST00000402696.3	c.2012G>A	p.Gly671Glu	0.019	0.002491	ID: 12,616. Conflicting interpretations of pathogenicity (Pathogenic/Likely benign). Atransferrinemia and transferrin variant B2	0.002 (D)	1 (D)	0.999 (D)	–
	CP	M14	rs139633388	ENST00000264613.6	c.2684G>C	p.Gly895Ala	0.019	0.001464	ID 42054. Conflicting interpretations. Aceruloplasminemi and deficiency of ferroxidase	0.008 (D)	1 (D)	1 (D)	–
	CP	M14	rs202217551	ENST00000264613.6	c.929G>A	p.Arg310His	0.019	0.0002017	ID 546261. Uncertain significance. Deficiency of ferroxidase	0.209 (T)	0.211 (B)	0.995 (D)	–
Altered in other amyloidotic diseases	ABCA1	M26	rs140365800	ENST00000374736.3	c.3053A>G	p.Asp1018Gly	0.019	0.0006329	ID 364423. Conflicting interpretations of pathogenicity (VUS or benign). Tangier disease and primary hypoalphalipoproteinemia	0.013 (D)	0.999 (D)	1 (D)	–
	APP	M2	rs200857049	ENST00000346798.3	c.446A>G	p.His149Arg	0.019	–	ID: 1,938,835. Uncertain significance. Alzheimer's disease	0.426 (D)	0.943 (D)	1 (D)	–
Chaperones	GC	M24	–	ENST00000504199.1	c.1184G>A	p.Cys395Tyr	0.019	–	–	0.018 (D)	1 (D)	1 (D)	–
	FGA	M12	rs748106542	ENST00000302053.3	c.514G>A	p.Asp172Asn	0.019	0.00006404	–	0.0 (D)	0.997 (D)	1 (D)	–
	FGA	M6	rs150073296	ENST00000302053.3	c.2285C>T	p.Ala762Val	0.019	0.0001698	–	0.001 (D)	0.967 (D)	1 (D)	–
	FGB	M20	–	ENST00000302068.4	c.676C>T	p.Pro226Ser	0.019	–	–	0.002 (D)	0.998 (D)	1 (D)	–

Table 1 (continued)

| Functional category	Gene	Sample	dbSNP ID	Transcript	Nucleotide change	Protein change	Allele Frequency in our study	MAFa in GnomAD v2.1.1	ClinVar Classification	SIFT[b]	PolyPhen-2[c]	Mutation Taster[d]	SpliceAI[e]
ECM components	ECM1	M6	rs144607263	ENST00000369047.4	c.1083C>T	p.Ala361= (splice region)	0.019	0.0000521	–	–	–	1 (D)	0 (Benign)
	FN1	M7	–	ENST00000354785.4	c.7304G>A	p.Gly2435Asp	0.019	–	–	0.192 (T)	0.967 (D)	1 (D)	–
	HSPG2	M6	–	ENST00000374695.3	c.7795G>A	p.Val2599Met	0.019	–	–	0.019 (D)	0.999 (D)	0.646 (D)	–
	MMP9	M16	rs1490219180	ENST00000372330.3	c.1159T>G	p.Phe387Val	0.019	0.00002804	–	0.003 (D)	0.071 (B)	1 (D)	–
Proteolysis	F2	M24	rs760923326	ENST00000311907.5	c.341C>T	p.Thr114Met	0.019	0.000003983	–	0.374 (T)	0.021 (B)	1 (N)	–
	PLAT	M16	–	ENST00000220809.4	c.920C>T	p.Pro307Leu	0.019	–	–	0.005 (D)	0.784 (D)	1 (D)	–
	PLAT	M26	rs61755432	ENST00000220809.4	c.1481G>C	p.Gly494Ala	0.019	0.0009440	ID: 810,282. Uncertain significance. Thrombocytopenia	0.182 (T)	0.98 (D)	0.999 (D)	–
	PSEN2	M12	rs150400387	ENST00000366783.3	c.184C>T	p.Arg62Cys	0.019	0.0002195	ID: 567,646. Alzheimer disease 4 and Dilated cardiomyopathy 1 V	0.012 (D)	0.877 (D)	0.803 (N)	–

[a] *MAF Minor Allele Frequency*

[b] SIFT score: <0.05 deleterious (D); >0.05 tolerated (T). For missense variants only

[c] PolyPhen2 score: <0.15 benign (B); >0.15 likely pathogenic (D). For missense variants only

[d] MutationTaster score: probability that the prediction is true, higher when close to 1. Likely pathogenic (D); Likely benign (N)

[e] Splice AI score: probability of the variant being splice-altering. From 0 to 1, higher when close to 1

Moreno-Gázquez *et al. BMC Research Notes*   (2023) 16:249

Page 5 of 8

Fig. 1 Matrix bubble plot displaying the genes where sequence variants were identified and their corresponding ATTRwt amyloidosis carrier patients (M). Genes are classified by color according to their functional group. *TF* Transferrin; *CP* Ceruloplasmin; *ABCA1* ATP binding cassette subfamily A member 1; *APP* Amyloid beta precursor protein; *GC* GC vitamin D binding protein; *FGA* Fibrinogen Alpha Chain; *FGB* Fibrinogen Beta Chain; *ECM1* Extracellular matrix protein 1; *FN1* Fibronectin 1; *F2* Coagulation factor II—thrombin; *FN1* Fibronectin 1; *HSPG2* Heparan sulfate proteoglycan 2; *MMP9* Matrix metallopeptidase 9; *F2* Coagulation factor II—thrombin; *PLAT* Plasminogen activator—tissue type; *PSEN2* Presenilin 2; *ECM* Extracellular matrix

genes encoding proteases *F2*, *PLAT* and *PSEN2*; the ECM components *ECM1*, *FN1*, *HSPG2* and *MMP9*; the extracellular chaperones *FGA* and *FGB*; the genes *CP* and *TF*, previously found altered in cardiac ATTR amyloidosis [9, 10]; and the genes *ABCA1*, *APP* and *GC*, found altered in Alzheimer's disease [11–13]. Detailed information of the VUS is shown in Table 1. All VUS were missense, excepting one synonymous variant affecting a splice site. While *CP*, *FGA* and *PLAT* genes exhibited 2 different variants each, only one variant was found in the rest of the genes.

All VUS appeared only once in our cohort of patients, being their allele frequency in our sample of 0.019 (Table 1). The variants located in the genes *APP*, *FGB*, *FN1*, *GC*, *HSPG2* and one of the two located in *PLAT* were novel, being to date absent in the GnomAD database.

Discussion

In this study we evaluated the presence and predicted pathogenicity of sequence variants in genes that could play a role in the pathogenic mechanisms of ATTRwt amyloidosis. Using a panel of 84 genes selected based on their potential relationship with the disease, we found 72 rare or novel variants associated for the first time with a cohort of ATTRwt amyloidosis patients (Additional file 1: Table S4). Among them, although no pathogenic variants were identified, 17 variants concerning the *ABCA1*, *APP*,

CP, *ECM1*, *F2*, *FGA*, *FGB*, *FN1*, *GC*, *HSPG2*, *MMP9*, *PLAT*, *PSEN2* and *TF* genes were further classified as VUS (Table 1).

A variant is classified as VUS when it does not fulfil all the criteria to be classified as pathogenic or benign, or because it exhibits conflicting evidence. Consistently, these VUS variants may be reclassified as new evidence on them are provided [8]. Therefore, their pathogenic role cannot be ruled out with the current knowledge, and further investigation would be instrumental to understand their clinical significance and relation to the ATTRwt aetiopathogenesis. Of the 17 VUS identified, 10 have been classified as potentially deleterious by all the variant pathogenicity prediction programs consulted: SIFT, PolyPhen-2 and MutationTaster, with high scores (Table 1).

Apart from the disease-specific peptide, amyloid deposits are composed of general amyloid-associated molecules, such as the serum amyloid P component (SAP), apolipoprotein E or ECM-related proteins [14]. Moreover, the deposition of amyloid takes place in the ECM of tissues and organs. We identified one VUS in the *ECM1* gene, which encodes the extracellular matrix protein 1; the *FN1* gene, encoding for fibronectin; the *HSPG2* gene, encoding the heparan sulfate proteoglycan (HSPG) 2 or perlecan; and the *MMP9*, which encodes the matrix metalloproteinase 9. Changes in the expression level of the *ECM1* gene have been associated

with various non-amyloidotic cardiac conditions [15, 16]. Regarding amyloidosis, Misumi et al. [17] observed that amyloid deposition of TTR induced an increased expression of ECM components including fibronectin in patients with ATTRV30M amyloidosis. An increased expression of *MMP9*, a previously known remodeler of the ECM [18] with capacity to degrade TTR aggregates and fibrils in vitro in the absence of SAP [14] has been also reported in both animal models and patients with ATTRV30M [14, 17, 19]. Interestingly, ECM1 has been shown to interact with MMP9 and to reduce the proteolytic activity of MMP9 in vitro [20], potentially being able to have an indirect effect on the deposits of TTR fibrils. HSPGs are glycoproteins found as components of amyloid deposits in most amyloidosis [21]. The highly sulfated domains of heparan sulfate and its analogue heparin interact with V30M TTR and recombinant TTRwt, and have been suggested to function as a scaffold for TTR fibril formation in ATTR amyloidosis and to foster TTR fibrillization [22, 23]. Interestingly, the selective heparin/heparan sulfate-TTR binding was stronger for the TTRwt peptide than for the equivalent carrying the V30M mutation [23]. Hence, the presence of a variant in the ECM proteins identified here as VUS, could induce changes in the binding or function activities of such proteins and eventually influence the formation of TTRwt amyloid fibrils.

*A*myloid deposits can be formed either by the complete TTR protein or TTR fragments [24, 25]. Some studies attribute TTR cleavage to trypsin-like serine proteases [26]. In our data, we found VUS in 3 genes encoding proteases: *PLAT* gene, encoding tissue plasminogen activator, *F2* gene, encoding prothrombin, and *PSEN2* gene, encoding Presenilin 2. Blood concentration of prothrombin has been reported lower in patients with ATTRwt amyloidosis in comparison to healthy controls and individuals with ATTRv amyloidosis [9]. Regarding Presenilin-2, it is part of the complex that catalyzes the cleavage of APP and mutations in *PSEN2* are causative of dominantly inherited Alzheimer's disease [27].

Extracellular chaperones stabilize misfolded proteins and guide them to specific cell receptors for their uptake and subsequent degradation. It has been suggested that their dysfunction may result in the deposition of misfolded proteins, influencing the development of amyloidosis disorders [28]. In this study, we identified 2 VUS in the *FGA* gene, and 1 in the *FGB*, coding for the alpha and beta chain of fibrinogen, respectively. Da Costa et al. [29] reported increased plasma concentrations of fibrinogen and other extracellular chaperones in patients with ATTRV30M. Concentrations of the alpha chain of fibrinogen were also higher in patients with ATTRv

amyloidosis when compared to the ATTRwt amyloidosis cohort [9]. In addition, mutations in *FGA* are associated with fibrinogen A α-chain amyloidosis, a type of hereditary renal amyloidosis [30].

It is also conceivable that there may be shared alterations with other amyloidotic disorders, such as Alzheimer's disease. We found VUS in the *ABCA1, APP* and *GC* genes, the three reported as altered in Alzheimer's disease [13, 31]. An impaired cleavage of APP protein results in the generation and extracellular secretion of β-amyloid that will ultimately assemble to form amyloid plaques [32]. Approximately 25 pathogenic variants in the *APP* gene have been associated to the etiology of Alzheimer's disease [12]. Curiously, it has been proposed that APPwt could function as a transcriptional regulator of TTRwt [33, 34]. Moreover, TTR deposits can co-exist with β-amyloid ones in patients with ATTRv amyloidosis [35].

Finally, we identified VUS in genes for which alterations have been reported in the literature in patients with ATTRwt amyloidosis, as it is the case of the *CP* gene, responsible for ceruloplasmin, and *TF* gene, coding for transferrin [9]. CP is increased in patients with ATTRwt amyloidosis relative to healthy controls [9]. For their part, Ohta et al. [10] reported the co-precipitation of transferrin with TTR amyloid in mouse models with TTRV30M and suggested that transferrin facilitates the destabilization of the secondary structure of TTR, contributing to fibrillogenesis.

In summary, this study provides novel data about the identification of variants in diverse protein-coding genes that we hypothesize might not be disease-causing, but do rather modulate or contribute to the development of ATTRwt amyloidosis. Although some of the selected genes have been previously assessed in ATTRv amyloidosis, this is the first time that variants in such genes are identified in patients with ATTRwt amyloidosis.

To conclude, our work can serve as a basis for future studies focused on unravelling the underlying mechanisms of TTR misfolding and expand the understanding of the disease.

Limitations

The present study has several limitations: (i) the size of our study cohort was small, (ii) the described variants should be further examined in non-disease-affected relatives of the patients under study, and (iii) the number of genes that could be included in the sequencing panel was limited. Thus, further investigation of the newly identified variants and the broadening of the targeted genes should be pursued in future studies.

Moreno-Gázquez *et al. BMC Research Notes*   (2023) 16:249

Page 7 of 8

Abbreviations

TTR   Transthyretin
ATTRwt   Wild-type ATTR amyloidosis
ATTRv   Variant ATTR amyloidosis
SNPs   Single nucleotide polymorphisms
ECM   Extracellular matrix
MAF   Minor allele frequency
GnomAD   Genome aggregation database
ACMG   American College of Medical Genetics
VUS   Variant of uncertain significance
APP   β-Amyloid precursor protein

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13104-023-06491-z.

Additional file 1: Table S1. Clinical features of the patients included in the study. **Table S2.** Genes included in the On-Demand panel, number of amplicons, number of bases and coverage. Genes are grouped by functional category. **Table S3.** Genes included in the Spike-in panel, number of amplicons, number of bases and coverage. Genes are grouped by functional category. **Table S4.** Characteristics of all variants found in the study.

Author contributions

IMG, RPP, SMG and MAAA designed the study. IMG and RPP selected the genes and designed the panel. ARUB, AAG and MAAA collected the blood samples. IMG and RPP analyzed the samples. IMG, RPP, LAQ and SMG analyzed data. IMG, RPP and LAQ wrote the manuscript. SMG, MAAA, and CLP reviewed and edited the manuscript. All authors have read and approved submission of the manuscript.

Availability of data and materials

The data generated from this study (list of identified variants) are available in Additional file 1: Table S4. Information of variants identified are openly available online at ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), dbSNP (https://www.ncbi.nlm.nih.gov/snp/) and gnomAD (http://gnomad.broadinstitute.org/) databases.

Declarations

Ethics approval and consent to participate

This study was reviewed and approved by the Research Ethics Committee of the Community of Aragon (CEICA) in accordance with the Declaration of Helsinki. All patients had signed an informed consent for blood collection for genetic testing.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests. Akcea Therapeutics has not influenced the design, performance, or conclusions of the present study.

References

1. Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015;12(2):91–102.
2. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–43.
3. Santos D, Coelho T, Alves-Ferreira M, Sequeiros J, Mendonça D, Alonso I, et al. Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M). Eur J Hum Genet. 2016;24(5):756–60.
4. Santos D, Coelho T, Alves-Ferreira M, Sequeiros J, Mendonça D, Alonso I, et al. Familial amyloid polyneuropathy in Portugal: new genes modulating age-at-onset. Ann Clin Transl Neurol. 2017;4(2):98–105.
5. Dardiotis E, Koutsou P, Zamba-papanicolaou E, Vonta I, Hadjivassiliou M, Hadjigeorgiou G, et al. Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. J Neurol Sci. 2009;284(1–2):158–62.
6. Dias A, Santos D, Coelho T, Alves-Ferreira M, Sequeiros J, Alonso I, et al. C1QA and C1QC modify age-at-onset in familial amyloid polyneuropathy patients. Ann Clin Transl Neurol. 2019;6(4):748–54.
7. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–12.
8. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405–24.
9. Chan GG, Koch CM, Connors LH. Blood proteomic profiling in inherited (ATTRm) and acquired (ATTRwt) forms of transthyretin-associated cardiac amyloidosis. J Proteome Res. 2017;16(4):1659–68.
10. Ohta M, Sugano A, Hatano N, Sato H, Shimada H, Niwa H, et al. Coprecipitation molecules hemopexin and transferrin may be key molecules for fibrillogenesis in TTR V30M amyloidogenesis. Transgenic Res. 2018;27(1):15–23.
11. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118(2):671–82.
12. Li NM, Liu KF, Qiu YJ, Zhang HH, Nakanishi H, Qing H. Mutations of beta-amyloid precursor protein alter the consequence of Alzheimer's disease pathogenesis. Neural Regen Res. 2019;14(4):658–65.
13. Moon M, Song H, Hong H, Nam D, Cha M-Y, Oh M, et al. Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology. Cell Death Differ. 2013;20(4):630–8.
14. Sousa MM, do Amaral JB, Guimarães A, Saraiva MJ. Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin, and matrix metalloproteinase-9 in familial amyloid polyneuropathy. FASEB J Off Publ Fed Am Soc Exp Biol. 2005;19(1):124–6.
15. Hardy SA, Mabotuwana NS, Murtha LA, Coulter B, Sanchez-Bezanilla S, Al-Omary MS, et al. Novel role of extracellular matrix protein 1 (ECM1) in cardiac aging and myocardial infarction. PLoS ONE. 2019;14(2):e0212230.
16. Ramirez TA, Jourdan-Le Saux C, Joy A, Zhang J, Dai Q, Mifflin S, et al. Chronic and intermittent hypoxia differentially regulate left ventricular inflammatory and extracellular matrix responses. Hypertens Res. 2012;35(8):811–8.
17. Misumi Y, Ando Y, Ueda M, Obayashi K, Jono H, Su Y, et al. Chain reaction of amyloid fibril formation with induction of basement membrane in familiar amyloidotic polyneuropathy. J Pathol. 2009;219(4):481–90.

Moreno-Gázquez *et al. BMC Research Notes*   (2023) 16:249

Page 8 of 8

18. Stamenkovic I. Extracellular matrix remodelling: The role of matrix metalloproteinases. J Pathol. 2003;200(4):448–64.
19. Cardoso I, Merlini G, Saraiva MJ. 4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 2003;17(8):803–9.
20. Fujimoto N, Terlizzi J, Aho S, Brittingham R, Fertala A, Oyama N, et al. Extracellular matrix protein 1 inhibits the activity of matrix metalloproteinase 9 through high-affinity protein/protein interactions. Exp Dermatol. 2006;15(4):300–7.
21. Zhang X, Li JP. Heparan sulfate proteoglycans in amyloidosis. Prog Mol Biol Transl Sci. 2010;93:309–34.
22. Kameyama H, Uchimura K, Yamashita T, Kuwabara K, Mizuguchi M, Hung SC, et al. The accumulation of heparan sulfate S-domains in kidney transthyretin deposits accelerates fibril formation and promotes cytotoxicity. Am J Pathol. 2019;189(2):308–19.
23. Noborna F, O'Callaghan P, Hermansson E, Zhang X, Ancsin JB, Damas AM, et al. Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proc Natl Acad Sci U S A. 2011;108(14):5584–9.
24. Mangione PP, Porcari R, Gillmore JD, Pucci P, Monti M, Porcari M, et al. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci U S A. 2014;111(4):1539–44.
25. Ihse E, Ybo A, Suhr O, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol. 2008;216(2):253–61.
26. Mangione PP, Verona G, Corazza A, Marcoux J, Canetti D, Giorgetti S, et al. Plasminogen activation triggers transthyretin amyloidogenesis in vitro. J Biol Chem. 2018;293(37):14192–9.
27. Cai Y, An SSA, Kim S. Mutations in presenilin 2 and its implications in Alzheimer's disease and other dementia-associated disorders. Clin Interv Aging. 2015;10:1163–72.
28. Wyatt AR, Yerbury JJ, Dabbs RA, Wilson MR. Roles of extracellular chaperones in amyloidosis. J Mol Biol. 2012;421(4–5):499–516.
29. da Costa G, Ribeiro-Silva C, Ribeiro R, Gilberto S, Gomes RA, Ferreira A, et al. Transthyretin amyloidosis: chaperone concentration changes and increased proteolysis in the pathway to disease. PLoS ONE. 2015;10(7):0125392.
30. Sivalingam V, Patel BK. Familial mutations in fibrinogen Aα (FGA) chain identified in renal amyloidosis increase in vitro amyloidogenicity of FGA fragment. Biochimie. 2016;1(127):44–9.
31. Wijesekara N, Kaur A, Westwell-Roper C, Nackiewicz D, Soukhatcheva G, Hayden MR, et al. ABCA1 deficiency and cellular cholesterol accumulation increases islet amyloidogenesis in mice. Diabetologia. 2016;59(6):1242–6.
32. Soria Lopez JA, González HM, Léger GC. Alzheimer's disease. Handb Clin Neurol. 2019;1(167):231–55.
33. Kerridge C, Belyaev ND, Nalivaeva N, Turner AJ. The Aβ-clearante protein transthyretin, like neprilysin, is epigenetically regulated by the amyloid precursor protein intracellular domain. J Neurochem. 2014;130:419–31.
34. Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE, et al. Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci U S A. 2010;107(40):17362–7.
35. Sakai K, Asakawa M, Rakahashi R, Ishida C, Nakamura R, Hamaguchi T, et al. Coexistence of transthyretin and aβ-type cerebral amyloid angiopahty in a patient with hereditary transthyretin V30M amyloidosis. J Neurol Sci. 2017;381:144–6.

Publisher's Note